.jpg)
Nov 13
Aravax Establishes Pharmaceutical Development base on the Oxford Science Park with a Focus on Developing Manufacturing Capabilities inthe UK
Melbourne, Australia and Oxford, UK– 14 November 2024, Aravax, a clinical-stage biotechnology company developing next-generation...
Oct 28
Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
Melbourne, Australia – 28 October 2024: Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies...
Apr 30
Aravax Appoints Dr Paul Laidler as VP Pharmaceutical Development
1 May 2024, Melbourne, Australia: Aravax, a clinical-stage biotechnology company developing next- generation immunotherapies which are...
Jan 23
Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
23 Jan 2024: Aravax, a clinical stage biotechnology company developing the first rationally designed and precisely targeted...
Jul 21, 2023
Aravax appoints Annette Leahy as Director of Clinical Operations
21 July 2023, Melbourne, Australia: Aravax, a clinical-stage biotechnology company developing next- generation immunotherapies which are...
May 31, 2023
Aravax doses first patient in Phase 2 peanut allergy clinical trials
1 June, Melbourne, Australia: The first patient has been dosed in a Phase 2 study (AVX-201) being run by biotechnology company Aravax,...